Fresnedo Olatz, Lopez-Gomez Jose Antonio, Ceniceros Carlos, Larrinaga Gorka, Saiz Alberto, Mosteiro Lorena, Navarro-Imaz Hiart, Rueda Yuri
Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Barrio Sarriena s/n, 48940, Leioa, Bizkaia, Spain.
Department of Nursing, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.
Sci Rep. 2025 Jul 9;15(1):24762. doi: 10.1038/s41598-025-09664-x.
Clear cell renal cell carcinoma (ccRCC) is characterized by the accumulation of high quantities of lipids in cytoplasmic lipid droplets. Owing to the tissue heterogeneity of ccRCC, adjacent biopsies from a tumor can diverge substantially in molecular characteristics. To elucidate metabolic alterations leading to extensive lipidomic changes in grade 2 human nephrectomies, we applied a dual lipidome-transcriptome analytical procedure that allows performing correlational studies of the two datasets. Linked to the mean 100 fold increase of esterified cholesterol (ChE) in ccRCC we found multiple significant correlations between ChE and the main membrane lipids that might be mediated by an increased capacity for lipid hydrolysis linked to lysosomes and the endoplasmic reticulum.Our results suggest that the accumulation of ChE from extracellular sources might be a determinant metabolic flux in low-grade ccRCC. ChE mobilization by non-canonical hydrolytic systems might confer increased metabolic flexibility to obtain free cholesterol and fatty acids. Based on correlations between lipidome and lipometabolic transcriptome, this study provides new perspectives for evaluating pharmacological lipid management as a future therapeutic approach for low-grade ccRCC treatment.
透明细胞肾细胞癌(ccRCC)的特征是细胞质脂滴中积累大量脂质。由于ccRCC的组织异质性,肿瘤相邻活检组织的分子特征可能存在很大差异。为了阐明导致2级人类肾切除术中广泛脂质组变化的代谢改变,我们应用了一种双脂质组-转录组分析程序,该程序允许对两个数据集进行相关性研究。与ccRCC中酯化胆固醇(ChE)平均增加100倍相关,我们发现ChE与主要膜脂之间存在多个显著相关性,这些相关性可能由与溶酶体和内质网相关的脂质水解能力增强介导。我们的结果表明,细胞外来源的ChE积累可能是低级别ccRCC中的一个决定性代谢通量。非经典水解系统对ChE的动员可能赋予增加的代谢灵活性以获得游离胆固醇和脂肪酸。基于脂质组和脂质代谢转录组之间的相关性,本研究为评估药物脂质管理作为低级别ccRCC治疗的未来治疗方法提供了新的视角。